June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
ROCK inhibitor enhances adhesion and wound healing on human corneal endothelial cells
Author Affiliations & Notes
  • Michael Nicolas
    Ophtalmology, Jules-Gonin eye hospital, Lausanne, Switzerland
  • Aurélien Pipparelli
    Ophtalmology, Jules-Gonin eye hospital, Lausanne, Switzerland
  • Yvan Arsenijevic
    Ophtalmology, Jules-Gonin eye hospital, Lausanne, Switzerland
  • Gilles Thuret
    Ophtalmology, University of St Etienne, St Etienne, France
  • Philippe Gain
    Ophtalmology, University of St Etienne, St Etienne, France
  • Francois Majo
    Ophtalmology, Jules-Gonin eye hospital, Lausanne, Switzerland
  • Footnotes
    Commercial Relationships Michael Nicolas, None; Aurélien Pipparelli, None; Yvan Arsenijevic, None; Gilles Thuret, None; Philippe Gain, None; Francois Majo, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1688. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael Nicolas, Aurélien Pipparelli, Yvan Arsenijevic, Gilles Thuret, Philippe Gain, Francois Majo; ROCK inhibitor enhances adhesion and wound healing on human corneal endothelial cells. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1688. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Recently it was reported that the ROCK inhibitor Y-27632 promotes adhesion, inhibits apoptosis, increases the number of proliferating monkey corneal endothelial cells in vitro and enhance corneal endothelial wound healing both in vitro and in vivo. Here, we proposed to evaluate the effects of ROCK inhibitor on HCEC either in vitro or ex vivo, firstly to assess the potential of this compound to increase the number of corneal graft available for the clinic and secondly to validate the previous results obtained in animal models, a step required before potential clinical application.

Methods: Using organ culture human cornea (N=34), the effect of ROCK inhibitor was evaluated either in vitro or ex vivo. Toxicity, endothelial cell density, cell proliferation, apoptosis, cell morphometry, adhesion and wound healing process were evaluated by live/dead assay standard cell counting method, EdU labelling, Ki67, Caspase3, Zo-1 and Actin immunostaining.

Results: In our study, we demonstrated for the first time in human endothelial cells ex vivo and in vitro, that ROCK inhibitor did not induce any toxicity effect and did not modulate metabolism activity. Compared to animal model, ROCK inhibitor treatment did not induce human endothelial cell proliferation. However, ROCK inhibitor significantly enhances corneal endothelial cell adhesion and wound healing.

Conclusions: These results strongly suggest that ROCK inhibitor is a promising and safe compound to improve the treatment of corneal endothelial dysfunction in human. ROCK inhibitor could be a potential therapeutic strategy in order to improve adhesion of transplanted human cultured endothelial cells. Furthermore, ROCK inhibitor treatment can increase in human the closure of endothelial cell defect.

Keywords: 481 cornea: endothelium • 503 drug toxicity/drug effects • 765 wound healing  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×